0
Signin
countryflagUS

18889881171

AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%

Kymera Therapeutics Inc

Healthcare US KYMR

35.21USD
-0.5(1.40%)

Last update at 2024-04-24T20:00:00Z

Day Range

34.6736.47
LowHigh

52 Week Range

9.6039.85
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -154.80800M -100.21700M -45.59300M -41.24600M -21.46700M
Minority interest - - - - -
Net income -151.83100M -97.99500M -43.94500M -41.29200M -21.46700M
Selling general administrative 43.83M 36.34M 18.23M 7.98M 3.77M
Selling and marketing expenses - - - - -
Gross profit 46.83M 72.83M 34.03M 2.93M -
Reconciled depreciation 2.98M 2.40M 1.76M 0.82M 0.20M
Ebit -161.25600M -100.53000M -46.30400M -42.20500M -21.45100M
Ebitda -154.63200M -100.04200M -45.47800M -40.37500M -21.24600M
Depreciation and amortization 6.62M 0.49M 0.83M 1.83M 0.20M
Non operating income net other 6.45M 0.31M 0.71M - -
Operating income -161.25600M -100.53000M -46.30400M -42.20500M -21.45100M
Other operating expenses 208.08M 173.36M 80.34M 45.14M 21.45M
Interest expense 0.18M 0.17M 0.12M 0.05M 0.02M
Tax provision - - - - -
Interest income 6.62M 0.49M 0.83M 1.00M 0.00000M
Net interest income 6.45M 0.31M 0.71M 0.96M -0.01600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.97700M -2.22200M -1.64800M 0.05M -
Total revenue 46.83M 72.83M 34.03M 2.93M 0.00000M
Total operating expenses 208.08M 173.36M 80.34M 45.14M 21.45M
Cost of revenue - - - - -
Total other income expense net 6.45M 0.31M 0.71M 0.96M -0.01600M
Discontinued operations - - - - -
Net income from continuing ops -154.80800M -100.21700M -45.59300M -41.24600M -21.46700M
Net income applicable to common shares -154.80800M -100.21700M -54.64300M -41.24600M -21.46700M
Preferred stock and other adjustments - - 9.05M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 603.13M 605.90M 487.18M 116.70M 44.23M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.71M 8.86M 5.56M 0.89M 0.38M
Total liab 112.98M 146.27M 203.29M 191.11M 78.67M
Total stockholder equity 490.15M 459.64M 283.89M -74.40600M -34.43600M
Deferred long term liab - - - - -
Other current liab -8.27800M -7.60400M -67.40200M 4.57M 0.01000M
Common stock 0.00600M 0.00500M 0.00400M - -
Capital stock 0.00600M 0.00500M 0.00400M 0.00000M 0.00000M
Retained earnings -383.79000M -228.98200M -128.76500M -76.45600M -35.21000M
Other liab 28.25M 39.36M 77.94M 29.64M 0.16M
Good will - - - - -
Other assets 9.15M 8.14M 1.62M 1.77M 0.20M
Cash 68.39M 47.98M 31.00M 76.02M 41.26M
Cash and equivalents - - - - -
Total current liabilities 63.26M 101.03M 110.62M 34.57M 4.69M
Current deferred revenue 63.26M 101.03M 170.39M 23.35M 2.32M
Net debt -51.06000M -30.01300M -13.01100M -54.82200M -40.56500M
Short term debt 3.94M 3.60M 3.26M 3.38M 0.30M
Short long term debt - - - - -
Short long term debt total 17.34M 17.96M 17.99M 21.19M 0.69M
Other stockholder equity 878.88M 689.27M -74.39800M 2.04M 0.77M
Property plant equipment 13.33M 11.88M 20.69M 22.08M 2.24M
Total current assets 559.49M 567.61M 302.34M 92.84M 41.79M
Long term investments 152.33M 125.19M 162.53M - -
Net tangible assets 490.15M 459.64M 283.89M -74.40600M -34.43600M
Short term investments 338.77M 394.44M 265.20M 15.94M 0.00000M
Net receivables 2.54M 0.14M 1.43M 0.29M 0.15M
Long term debt - - - - -
Inventory -12.25000M -8.99000M -163.38700M - -
Accounts payable 4.33M 4.00M 4.37M 3.28M 2.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.94900M -0.66000M -0.12800M 0.00600M -0.22400M
Additional paid in capital - - - - -
Common stock total equity 0.00600M 0.00500M 0.00400M - -
Preferred stock total equity - - - - -
Retained earnings total equity -383.79000M -228.98200M -128.76500M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -122.02200M -98.76800M 11.46M 1.77M 0.20M
Deferred long term asset charges - - - - -
Non current assets total 43.64M 38.30M 184.84M 23.86M 2.44M
Capital lease obligations 17.34M 17.96M 17.99M 21.19M 0.69M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 20.52M -98.23800M -422.58800M -15.95400M -15.95400M
Change to liabilities 5.03M 12.74M 118.39M 53.90M 0.82M
Total cashflows from investing activities 20.52M -99.83500M -422.58800M -16.48600M -1.35600M
Net borrowings -1.13000M -0.84900M -0.55400M -0.37100M -0.29500M
Total cash from financing activities 153.00M 250.28M 289.26M 34.91M 52.93M
Change to operating activities 2.30M 6.08M 7.91M 2.79M 1.63M
Net income -154.80800M -100.21700M -45.59300M -41.24600M -21.46700M
Change in cash 20.43M 21.50M -45.19600M 36.33M 33.71M
Begin period cash flow 54.09M 32.59M 77.79M 41.46M 7.75M
End period cash flow 74.53M 54.09M 32.59M 77.79M 41.46M
Total cash from operating activities -153.08500M -128.94600M 88.13M 17.91M -17.86300M
Issuance of capital stock 149.82M 243.11M 289.65M 35.21M 53.23M
Depreciation 2.98M 2.40M 1.76M 0.82M 0.20M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - 8.71M 6.88M - -
Change to account receivables -2.40100M 0.58M -0.57700M -1.43300M -0.14800M
Sale purchase of stock 4.30M 8.02M 276.29M - -
Other cashflows from financing activities 4.30M 8.02M 93.14M 35.28M 53.23M
Change to netincome 35.48M 24.99M 7.09M 1.64M 1.09M
Capital expenditures 2.84M 1.60M 9.10M 0.53M 1.36M
Change receivables - 0.58M -0.57700M - -
Cash flows other operating -41.76300M -69.43200M 120.40M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 20.43M 21.50M -45.19600M - -
Change in working capital -37.62300M -61.92300M 124.87M 56.69M 2.31M
Stock based compensation 35.48M 24.97M 5.19M 1.20M 0.65M
Other non cash items 0.89M 5.83M 0.33M 0.44M 0.44M
Free cash flow -155.92100M -130.54300M 79.03M 17.37M -19.21900M

Fundamentals

  • Previous Close 35.71
  • Market Cap1426.03M
  • Volume344675
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-182.55600M
  • Revenue TTM46.85M
  • Revenue Per Share TTM0.81
  • Gross Profit TTM -117.42200M
  • Diluted EPS TTM-2.86

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
KYMR
Kymera Therapeutics Inc		 -0.5 1.40% 35.21 - - 30.02 3.44 23.15 -6.6234
NVO
Novo Nordisk A/S		 -2.48 1.93% 126.16 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.58 1.23% 126.80 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.15 1.02% 400.76 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 -0.61 0.67% 90.10 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics Inc

200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472

Key Executives

Name Title Year Born
Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D. Co-Founder & Chairman 1974
Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, Pres, CEO & Director 1979
Mr. Bruce N. Jacobs CFA Chief Financial Officer NA
Dr. Jared A. Gollob M.D. Chief Medical Officer 1965
Ms. Elaine Caughey Chief Bus. Officer NA
Kevin Dushney Sr. VP of IT & Operations NA
Mr. Michael J. Todisco VP of Accounting & Fin. 1965
Mr. Vijay Sabesan Sr. VP of Technical Operations 1972
Ms. Melissa Brody VP of Bus. Devel. NA
Ms. Karen Weisbach VP of People & Culture NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).